Practice Fusion And AstraZeneca Partner for PHM Initiative For Asthma, COPD

Practice Fusion And AstraZeneca Partner for PHM Initiative For Asthma, COPD

astrazenecaPractice Fusion, an Electronic Health Records (EHR) provider, and AstraZeneca recently renounced a Population Health Management (PHM) program for members of Practice Fusion’s community that includes about 112,000 medical professionals. The program provides data-driven insights that can assist members in their commitment to improving care for those suffering with chronic obstructive pulmonary disease (COPD) or asthma.

The program is sponsored by AstraZeneca and being advanced by Practice Fusion, aiming to identify individuals whose current COPD or asthma care does not match evidence-based clinical guidelines, and make physicians aware of the stage of care within the EHR platform and via patient charts. These alerts take into account the clinical guidelines from both the National Heart, Lung, and Blood Institute and the Global Initiative for Chronic Obstructive Lung Disease.

Practitioners will also be allowed to access a dashboard included in the Practice Fusion EHR platform that displays aggregate views of their patients’ health in real-time. Thanks to this dashboard, providers can consult the percentage of their patients suffering from COPD and asthma and those whose care meets evidence-based clinical guidelines. Additionally, it will be possible for clinicians to compare their patient populations’ percentages with similar patient populations that are also being registered in the platform.

[adrotate group=”11″]

Estimates by the Asthma and Allergy Foundation of America suggest that almost 25 million people in the United States suffer from asthma and that over 3,300 deaths are due to this disease, each year. A report published in March 2013 by the American Lung Association found that COPD is the 3rd leading cause of death in the United States and over 12 million adults in America have been diagnosed with COPD.

Read More News Concerning AstraZeneca

AstraZeneca recently presented encouraging data from its phase III PINNACLE program focused on evaluating PT003 as a potential treatment for chronic obstructive pulmonary disease (COPD). The program is comprised of two 24-week pivotal studies, entitled PINNACLE 1 and PINNACLE 2, and the top-line results revealed its effectiveness in improving patients’ lung function.

The PINNACLE 1 and PINNACLE 2 studies had as their primary objective the evaluation of lung function benefits, measured by the trough forced expiratory volume in one-second (FEV1), as announced by the company in a press release.

Leave a Comment